Richard Law
Stock Analyst at Goldman Sachs
(2.31)
# 2,528
Out of 4,858 analysts
64
Total ratings
37.93%
Success rate
2.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $4.08 | +341.18% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $5.20 | -42.31% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.03 | +329.04% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $20.42 | +51.81% | 3 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $31 → $27 | $16.09 | +67.81% | 3 | May 7, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $28.95 | +3.63% | 1 | Apr 8, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $82 → $73 | $44.17 | +65.27% | 3 | Feb 27, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $28 → $24 | $15.55 | +54.39% | 6 | Feb 13, 2025 | |
| MRUS Merus | Initiates: Buy | $73 | $55.05 | +32.61% | 1 | Nov 21, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $5.03 | +118.69% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $31 | $6.39 | +385.13% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $17.89 | +162.72% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $41.52 | +51.73% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $48.39 | -23.54% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $8.37 | +808.00% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.03 | +589.66% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $7.67 | +695.31% | 4 | May 8, 2023 |
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $4.08
Upside: +341.18%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $5.20
Upside: -42.31%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.03
Upside: +329.04%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $20.42
Upside: +51.81%
Viridian Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $31 → $27
Current: $16.09
Upside: +67.81%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $28.95
Upside: +3.63%
MoonLake Immunotherapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $82 → $73
Current: $44.17
Upside: +65.27%
Mineralys Therapeutics
Feb 13, 2025
Maintains: Buy
Price Target: $28 → $24
Current: $15.55
Upside: +54.39%
Merus
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $55.05
Upside: +32.61%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $5.03
Upside: +118.69%
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $6.39
Upside: +385.13%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $17.89
Upside: +162.72%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $41.52
Upside: +51.73%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $48.39
Upside: -23.54%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $8.37
Upside: +808.00%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.03
Upside: +589.66%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $7.67
Upside: +695.31%